More tools:Markets·Screener·Research·Chat

Onconetix, Inc. Common Stock (ONCO) Financial Statements

Onconetix, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00PNSYQK0
XNAS · usd
0.78▼ 0.03 (-3.60%)
As of 2026-09-10
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.81
Day's Range0.80 – 0.84
52-Week Range0.09 – 6.73
Volume262.8K
Avg Volume387.6K
Share Statistics
Shares Outstanding
Employees2
ExchangeXNAS
Listed2022-02-18
Share count as of August 13, 2026
Loading Income Statement…
Key questions about Onconetix, Inc. Common Stock (ONCO)
What is Onconetix, Inc. Common Stock's Market Cap?
Onconetix, Inc. Common Stock's Market Cap is $3.1M, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's Price / Sales?
Onconetix, Inc. Common Stock's Price / Sales is 4.2×, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's Revenue (TTM)?
Onconetix, Inc. Common Stock's Revenue (TTM) is $735.2K, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's Net Income (TTM)?
Onconetix, Inc. Common Stock's Net Income (TTM) is -$9.7M, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's EBITDA?
Onconetix, Inc. Common Stock's EBITDA is -$15.5M, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's Diluted EPS (TTM)?
Onconetix, Inc. Common Stock's Diluted EPS (TTM) is -2.46, based on as-reported figures from SEC (XBRL) filings.
What is Onconetix, Inc. Common Stock's EBITDA Margin?
Onconetix, Inc. Common Stock's EBITDA Margin is -2107.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-83.9%-78.9%-57.4%-25.4%
Cost of revenue
Gross profit
% of revenue25.1%-7.7%81.6%88.6%
Operating expenses
Selling, general, and administrative
Research and development
Impairment of goodwill
Total operating expenses
% of revenue15976.0%47649.5%503.6%770.0%
Loss from operations
% of revenue-15950.9%-47657.2%-422.1%-681.5%
Other (expense) income
Interest expense
Change in fair value of subscription agreement liability – related party————
Change in fair value of contingent warrant liabilities
Change in fair value of Series D Derivative Liability
Change in fair value of Series E Derivative Liability——
Gain on forgiveness of accounts payable——
Other income (loss)
Total other income (loss)
Loss before income taxes
Net loss
% of revenue-16748.3%-19643.4%1867.5%-2892.7%
Deemed dividend Series C preferred stock——
Net loss applicable to common stockholders
Net loss per share, basic (in Dollars per share)
Net loss per share, diluted (in Dollars per share)